請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68839完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李章銘 | |
| dc.contributor.author | Ting-Yu Lu | en |
| dc.contributor.author | 呂庭聿 | zh_TW |
| dc.date.accessioned | 2021-06-17T02:37:58Z | - |
| dc.date.available | 2017-09-12 | |
| dc.date.copyright | 2017-09-12 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-08-17 | |
| dc.identifier.citation | Ahmad, U., Yao, X., Detterbeck, F., Huang, J., Antonicelli, A., Filosso, P. L., . . . Rimner, A. (2015). Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg, 149(1), 95-100, 101 e101-102. doi:10.1016/j.jtcvs.2014.09.124
Bedano, P. M., Perkins, S., Burns, M., Kessler, K., Nelson, R., Schneider, B. P., ... & Loehrer, P. J. (2008). A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. . Journal of Clinical Oncology, 26(15_suppl), 19087-19087. Bernard, C., Frih, H., Pasquet, F., Kerever, S., Jamilloux, Y., Tronc, F., . . . Seve, P. (2016). Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev, 15(1), 82-92. doi:10.1016/j.autrev.2015.09.005 Chao, Y. K., Liu, Y. H., Hsieh, M. J., Wu, Y. C., Chen, T. P., Lu, M. S., . . . Liu, H. P. (2015). Long-term outcomes after thoracoscopic resection of stage I and II thymoma: a propensity-matched study. Ann Surg Oncol, 22(4), 1371-1376. doi:10.1245/s10434-014-4068-9 Engels, E. A. (2010). Epidemiology of thymoma and associated malignancies. J Thorac Oncol, 5(10 Suppl 4), S260-265. doi:10.1097/JTO.0b013e3181f1f62d Engels, E. A., & Pfeiffer, R. M. (2003). Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer, 105(4), 546-551. doi:10.1002/ijc.11099 Flowers, L. O., Subramaniam, P. S., & Johnson, H. M. (2005). A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene, 24(12), 2114-2120. doi:10.1038/sj.onc.1208437 Giaccone, G., Rajan, A., Ruijter, R., Smit, E., van Groeningen, C., & Hogendoorn, P. C. (2009). Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol, 4(10), 1270-1273. doi:10.1097/JTO.0b013e3181b6be57 Girard, N., Shen, R., Guo, T., Zakowski, M. F., Heguy, A., Riely, G. J., . . . Pao, W. (2009). Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res, 15(22), 6790-6799. doi:10.1158/1078-0432.CCR-09-0644 Girard, N., Teruya-Feldstein, J., Payabyab, E. C., Riely, G. J., Rusch, V. W., Kris, M. G., & Zakowski, M. F. (2010). Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol, 5(9), 1439-1446. doi:10.1097/JTO.0b013e3181e392a8 Greene, M. A., & Malias, M. A. (2003). Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg, 125(2), 434-436. doi:10.1067/mtc.2003.133 Hamaji, M. (2016). The role of adjuvant chemotherapy following resection of early stage thymoma. Ann Cardiothorac Surg, 5(1), 45-50. doi:10.3978/j.issn.2225-319X.2015.09.03 Heinrich, M. C., Owzar, K., Corless, C. L., Hollis, D., Borden, E. C., Fletcher, C. D., . . . Fletcher, J. A. (2008). Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol, 26(33), 5360-5367. doi:10.1200/JCO.2008.17.4284 Henley, J. D., Cummings, O. W., & Loehrer, P. J., Sr. (2004). Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol, 130(4), 222-224. doi:10.1007/s00432-004-0545-z Henson, E., Chen, Y., & Gibson, S. (2017). EGFR Family Members' Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer. Cancers (Basel), 9(4). doi:10.3390/cancers9040027 Hung1, Y.-S., , C.-L. C., , H. C., , C.-H. L., , P.-T. C., & , W.-C. C. (2009). Thymic tumor. Taiwan Society of Internal Medicine. Ionescu, D. N., Sasatomi, E., Cieply, K., Nola, M., & Dacic, S. (2005). Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer, 103(3), 630-636. doi:10.1002/cncr.20811 Kario, E., Marmor, M. D., Adamsky, K., Citri, A., Amit, I., Amariglio, N., . . . Yarden, Y. (2005). Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem, 280(8), 7038-7048. doi:10.1074/jbc.M408575200 Kazi, J. U., Kabir, N. N., Flores-Morales, A., & Ronnstrand, L. (2014). SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci, 71(17), 3297-3310. doi:10.1007/s00018-014-1619-y Khalil, A. A., Kabapy, N. F., Deraz, S. F., & Smith, C. (2011). Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta, 1816(2), 89-104. doi:10.1016/j.bbcan.2011.05.001 Kim, E. S., Putnam, J. B., Komaki, R., Walsh, G. L., Ro, J. Y., Shin, H. J., . . . Shin, D. M. (2004). Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer, 44(3), 369-379. doi:10.1016/j.lungcan.2003.12.010 Kondo, K., & Monden, Y. (2003). Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg, 76(3), 878-884; discussion 884-875. Kurup, A., Burns, M., Dropcho, S., Pao, W., & Loehrer, P. J. . (2005). Phase II study of gefitinib treatment in advanced thymic malignancies. Journal of Clinical Oncology, 23(90160), 7068-7068. Liang, P., Cheng, S. H., Cheng, C. K., Lau, K. M., Lin, S. Y., Chow, E. Y., . . . Ng, M. H. (2013). Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica, 98(2), 288-295. doi:10.3324/haematol.2012.065607 Liu, T. J., Lin, M. W., Hsieh, M. S., Kao, M. W., Chen, K. C., Chang, C. C., . . . Lee, J. M. (2014). Video-assisted thoracoscopic surgical thymectomy to treat early thymoma: a comparison with the conventional transsternal approach. Ann Surg Oncol, 21(1), 322-328. doi:10.1245/s10434-013-3228-7 Lombe, D. C., & Jeremic, B. (2015). A Review of the Place and Role of Radiotherapy in Thymoma. Clin Lung Cancer, 16(6), 406-412. doi:10.1016/j.cllc.2015.05.003 Mao, Z. F., Mo, X. A., Qin, C., Lai, Y. R., & Hackett, M. L. (2012). Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol, 8(3), 161-169. doi:10.3988/jcn.2012.8.3.161 Masaoka, A., Monden, Y., Nakahara, K., & Tanioka, T. (1981). Follow-up study of thymomas with special reference to their clinical stages. Cancer, 48(11), 2485-2492. McCart, J. A., Gaspar, L., Inculet, R., & Casson, A. G. (1993). Predictors of survival following surgical resection of thymoma. J Surg Oncol, 54(4), 233-238. Mimae, T., Tsuta, K., Kondo, T., Nitta, H., Grogan, T. M., Okada, M., . . . Tsuda, H. (2012). Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. Ann Oncol, 23(12), 3129-3137. doi:10.1093/annonc/mds147 Moore, K. H., McKenzie, P. R., Kennedy, C. W., & McCaughan, B. C. (2001). Thymoma: trends over time. Ann Thorac Surg, 72(1), 203-207. Onuki, T., Ishikawa, S., Yamamoto, T., Ito, H., Sakai, M., Onizuka, M., . . . Ohara, K. (2008). Pathologic radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol, 3(3), 270-276. doi:10.1097/JTO.0b013e3181653c8c Pan, C. C., Chen, P. C., Wang, L. S., Lee, J. Y., & Chiang, H. (2003). Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology, 43(2), 165-172. Papadakis, K. A., Prehn, J., Nelson, V., Cheng, L., Binder, S. W., Ponath, P. D., . . . Targan, S. R. (2000). The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol, 165(9), 5069-5076. Porter, J. R., Fritz, C. C., & Depew, K. M. (2010). Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol, 14(3), 412-420. doi:10.1016/j.cbpa.2010.03.019 Rajan, A., Berman, A. W., Kelly, R. J., Lopez-Chavez, A., Dechowdhury, R., Chen, H., & Giaccone, G. . (2010). Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC). . Journal of Clinical Oncology, 28(15_suppl), e17525-e17525. Raza, A., & Woo, E. (2016). Video-assisted thoracoscopic surgery versus sternotomy in thymectomy for thymoma and myasthenia gravis. Ann Cardiothorac Surg, 5(1), 33-37. doi:10.3978/j.issn.2225-319X.2015.10.01 Remon, J., Girard, N., Mazieres, J., Dansin, E., Pichon, E., Grellier, L., . . . Besse, B. (2016). Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer, 97, 99-104. doi:10.1016/j.lungcan.2016.04.024 Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. . (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. . Critical reviews in oncology/hematology, 19(3), 183-232. Sasaki, H., Yukiue, H., Kobayashi, Y., Nakashima, Y., Moriyama, S., Kaji, M., . . . Fujii, Y. (2001). Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today, 31(11), 1038-1040. doi:10.1007/s005950170021 Schmitt, J., & Loehrer, P. J., Sr. (2010). The role of chemotherapy in advanced thymoma. J Thorac Oncol, 5(10 Suppl 4), S357-360. doi:10.1097/JTO.0b013e3181f21129 Strobel, P., Bargou, R., Wolff, A., Spitzer, D., Manegold, C., Dimitrakopoulou-Strauss, A., . . . Marx, A. (2010). Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer, 103(2), 196-200. doi:10.1038/sj.bjc.6605740 Strobel, P., Hohenberger, P., & Marx, A. (2010). Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol, 5(10 Suppl 4), S286-290. doi:10.1097/JTO.0b013e3181f209a8 Suzuki, E., Sasaki, H., Kawano, O., Endo, K., Haneda, H., Yukiue, H., . . . Fujii, Y. (2006). Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol, 36(6), 351-356. doi:10.1093/jjco/hyl028 Venuta, F., Anile, M., Diso, D., Vitolo, D., Rendina, E. A., De Giacomo, T., . . . Coloni, G. F. (2010). Thymoma and thymic carcinoma. Eur J Cardiothorac Surg, 37(1), 13-25. doi:10.1016/j.ejcts.2009.05.038 W, B. E., Harris CC. (2004). WHO classification of tumors. Pathology and genetics of tumours of the lung, thymus and heart. Vol 7 ed. Lyon IARC. Wang, M. H., Wang, D., & Chen, Y. Q. (2003). Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis, 24(8), 1291-1300. doi:10.1093/carcin/bgg089 Weissferdt, A., Lin, H., Woods, D., Tang, X., Fujimoto, J., Wistuba, II, & Moran, C. A. (2012). HER family receptor and ligand status in thymic carcinoma. Lung Cancer, 77(3), 515-521. doi:10.1016/j.lungcan.2012.05.108 Yao, H. P., Zhou, Y. Q., Zhang, R., & Wang, M. H. (2013). MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer, 13(7), 466-481. doi:10.1038/nrc3545 Yen, Y. T., Lai, W. W., Wu, M. H., Lin, M. Y., Chang, J. M., Hsu, I. L., & Tseng, Y. L. (2011). Thymic neuroendocrine carcinoma and thymoma are both associated with increased risk of extrathymic malignancy: a 20-year review of a single institution. Ann Thorac Surg, 91(1), 219-225. doi:10.1016/j.athoracsur.2010.09.025 Yoh, K., Nishiwaki, Y., Ishii, G., Goto, K., Kubota, K., Ohmatsu, H., . . . Saijo, N. (2008). Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer, 62(3), 316-320. doi:10.1016/j.lungcan.2008.03.013 Zettl, A., Strobel, P., Wagner, K., Katzenberger, T., Ott, G., Rosenwald, A., . . . Marx, A. (2000). Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol, 157(1), 257-266. doi:10.1016/S0002-9440(10)64536-1 Zhan, P., Chen, X., Wu, X. Y., Hou, Z. B., Qian, Q., Zhang, Y., . . . Xie, H. Y. (2016). Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population. Clin Respir J. doi:10.1111/crj.12569 Zucali, P. A., Petrini, I., Lorenzi, E., Merino, M., Cao, L., Di Tommaso, L., . . . Giaccone, G. (2010). Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer, 116(20), 4686-4695. doi:10.1002/cncr.25367 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68839 | - |
| dc.description.abstract | 胸腺腫瘤，包括胸腺瘤與胸腺癌為發生於縱膈腔之罕見腫瘤。由於發生率較低，目前全球都較少有系統性之單中心或多中心的病例研究，關於台灣本土案例的特徵，亦缺乏大樣本數的資料；我們在臨床上觀察到，胸腺腫瘤患者的表現大相逕庭，就算擁有相同的細胞型態，往往卻也表現不同的惡性程度與預後。
手術治療一直以來都是胸腺腫瘤的標準治療，完整的腫瘤切除提供了非常好的預後；然而，手術以外的輔助療法，只有手術後的放射線治療被證明確實對預後有幫助，其餘已知的化學治療、標靶治療都無法達到顯著的治療效果。為了得到更多關於這個疾病的知識，我們擬執行此病例研究，探討本土胸腺腫瘤案例的特徵。此外，我們也會從胸腺腫瘤病人組織中，探查一些參與癌化的因子之表現情形，藉以尋找可能的標靶治療方向。 結合台灣大學醫學院附設醫院以及中國醫藥大學附設醫院的胸腺腫瘤患者共155 人，針對其臨床因子做分析，在分子生物研究方面，執行 RNA 之全基因陣列分析、血清之酵素免疫分析法、組織之免疫組織染色分析、組織癌化相關蛋白質表現之西方墨點分析。 藉由此病例研究，我們認識了本土胸腺腫瘤病例的臨床表現特徵，可以幫助在未來找出高風險、預後較差的患者族群，提供適當的醫療與追蹤策略；並根據分子生物學的研究結果，針對 SOCS5、RON、HSP90 等治療標的於胸腺腫瘤上的特殊表現做進一步的分析，希望有朝一日，可以應用在胸腺腫瘤患者的治療上。 | zh_TW |
| dc.description.abstract | Thymic epithelial tumors, including thymomas and thymic carcinomas, are rare epithelial tumors of the thymus. Adequate surgical resection is the main treatment of this tumor. However, there is no effective target therapy for thymic tumor according to previous research. Because of its rarity and low grade malignant, there are only few researches of thymus in Taiwan. In order to find out the clinical features of Taiwanese patients, and potential treatment targets, we are going to perform this study.
A total of 155 patients from National Taiwan University Hospital and China Medical University Hospital are included. According to our analysis, WHO classification and Masaoka stage are still the potential predictors of survival. Residence of patients and type II DM maybe correlate with invasiveness of tumor. According to our molecular biological results, unique expression features of SOCS5, RON and HSP90 in thymic tumor tissue are detected by Western blot. Synchronous performance of EGFR and SOCS5 are found in 6 pairs of tissue. Interesting, overexpression of HSP90 in tumor part is found in 7 pairs of tissue, which has never been reported. These may be the potential therapeutic target of this disease in the future. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T02:37:58Z (GMT). No. of bitstreams: 1 ntu-106-P03421003-1.pdf: 8308640 bytes, checksum: 2cafb2ec9167597984161cf26ec4b645 (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 口試委員會審定書………………………………………… i
誌謝………………………………………………………… ii 中文摘要…………………………………………………… iii 英文摘要…………………………………………………… iv 第一章 緒論 1 - 1 胸腺腫瘤的流行病學………………………… 1 1 - 2 胸腺腫瘤的臨床症狀………………………… 1 1 - 3 胸腺腫瘤的組織學分類與臨床分期………… 2 1 - 4 胸腺腫瘤的預後……………………………… 3 1 - 5 胸腺腫瘤的手術治療………………………… 4 1 - 6 胸腺腫瘤的放射線治療……………………… 4 1 - 7 胸腺腫瘤的化學治療………………………… 5 1 - 8 胸腺腫瘤的基因表現………………………… 6 1 - 9 胸腺腫瘤標靶治療的試驗進展……………… 6 1 - 10 研究目的……………………………………… 8 第二章 研究方法與材料 2 - 1 病例族群……………………………………… 9 2 - 2 臨床資料以及組織取得……………………… 9 2 - 3 分子生物研究方法…………………………… 10 2 - 4 統計分析……………………………………… 12 第三章 研究結果 3 - 1 臨床因子分析………………………………… 13 3 - 2 RNA 之全基因陣列分析……………………… 14 3 - 3 血清之酵素免疫分析法……………………… 15 3 - 4 組織之免疫組織染色分析…………………… 15 3 - 5 組織癌化相關蛋白質表現之西方墨點分析… 16 第四章 討論 4 - 1 臨床因子……………………………………… 19 4 - 2 分子生物研究………………………………… 20 4 - 3 遭遇的困難與限制…………………………… 22 第五章 結論與展望……………………………………….. 24 參考文獻…………………………………………………… 25 表目錄 圖目錄 | |
| dc.language.iso | zh-TW | |
| dc.subject | 胸腺腫瘤 | zh_TW |
| dc.subject | 胸腺瘤 | zh_TW |
| dc.subject | 胸腺癌 | zh_TW |
| dc.subject | thymic carcinoma | en |
| dc.subject | Thymic tumor | en |
| dc.subject | thymoma | en |
| dc.title | 本土胸腺腫瘤之臨床特徵與潛力標靶治療方向之研究 | zh_TW |
| dc.title | Study of Clinical Features and Potential Therapeutic Target of Thymic Tumors | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊偉勛,方信元 | |
| dc.subject.keyword | 胸腺腫瘤,胸腺瘤,胸腺癌, | zh_TW |
| dc.subject.keyword | Thymic tumor,thymoma,thymic carcinoma, | en |
| dc.relation.page | 46 | |
| dc.identifier.doi | 10.6342/NTU201703781 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-08-17 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 未授權公開取用 | 8.11 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。